AbCellera Biologics (ABCL) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed AbCellera Biologics (ABCL) over the past year, gaining 226.6% versus a gain of 112.3%. Over five years, TNGX leads with a +60.9% price change compared with -19.2% for ABCL. AbCellera Biologics is the larger company by market cap ($4.07 billion vs $4.01 billion), about 1.0 times the size.
Tango Therapeutics converts more of its revenue into profit, with a net margin of -162.9% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | TNGX |
|---|---|---|
| Share price | $12.55 | $23.81 |
| Market cap | $4.07B | $4.01B |
| 1-day change | +4.37% | +5.49% |
| YTD return | +266.81% | +154.74% |
| 1-year return | +112.27% | +226.63% |
| 5-year return | -19.22% | +60.87% |
| EPS (TTM) | $-0.54 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $62.38M |
| Revenue growth (YoY) | +160.56% | +48.29% |
| Net income (latest FY) | $-146.41M | $-101.59M |
| Operating margin | -288.98% | -178.39% |
| Net margin | -194.88% | -162.85% |
| 52-week high | $15.02 | $34.39 |
| 52-week low | $2.75 | $6.69 |
| Distance from 52-week high | -16.45% | -30.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +33.12% | +89.75% |
| Average volume | 6.71M | 2.65M |
| Shares outstanding | 324.05M | 168.61M |
| Employees | 562 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed ABCL by 114.4 percentage points over the past year.
- Tango Therapeutics is more profitable, keeping -162.9 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +48.29%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
ABCL vs TNGX FAQ
Which is bigger, AbCellera Biologics or Tango Therapeutics?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $4.07B compared with $4.01B for Tango Therapeutics (TNGX).
Which stock has performed better over the past year, ABCL or TNGX?
TNGX returned +226.63% over the past 12 months, compared with +112.27% for ABCL (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.